Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07000084 2026-06-02

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

236 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06972615 2026-05-28

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Phase 2 Recruiting

37 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06929286 2026-05-11

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting

125 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05538663 2026-05-05

BRIDGE

Phase 3 Active not recruiting

870 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Completed

51 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04386746 2025-11-17

GEMDOCE

Phase 2 Active not recruiting

27 enrolled 9 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

31 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Clinical Trials

SunRISe-5

MoonRISe-1

MoonRISe-3

GAIN-BCG

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

BRIDGE

ADAPT-BLADDER

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

GEMDOCE

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

OHAI-NMIBC-01

BCG-TIME